Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

NOVUS BIOLOGICALS, LLC

Subsidiary ofBIO-TECHNE CORPORATIONUEI: RS5NG7AAY8C7CAGE: 3LVR5

NOVUS BIOLOGICALS, LLC is a federal contractor, registered under UEI RS5NG7AAY8C7 and CAGE code 3LVR5. It has been awarded $90,975 in federal contracts. Primary work spans Unknown NAICS, Research and Development in Biotechnology, and In-Vitro Diagnostic Substance Manufacturing. Top awarding agencies include Department Of Veterans Affairs, Department Of Defense, and Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

RS5NG7AAY8C7

CAGE Code

3LVR5

Entity Structure

Partnership or Limited Liability Partnership

Established

N/A

Business Classifications

For Profit OrganizationLimited Liability Company

NAICS Codes

325414Biological Product (except Diagnostic) Manufacturing(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

NOVUS BIOLOGICALS, LLC specializes in the development and manufacturing of biological research reagents and diagnostic components, operating within the pharmaceutical and life sciences manufacturing sector under NAICS 325414. Their core capabilities center on the production of high-purity antibodies...

NOVUS BIOLOGICALS, LLC specializes in the development and manufacturing of biological research reagents and diagnostic components, operating within the pharmaceutical and life sciences manufacturing sector under NAICS 325414. Their core capabilities center on the production of high-purity antibodies, recombinant proteins, and cell culture media optimized for research and in vitro diagnostic applications. The company demonstrates technical expertise in bioprocessing, purification chromatography, sterile manufacturing, and quality control systems aligned with cGMP standards. Their differentiation lies in scalable, GMP-compliant production of niche biological reagents for academic, clinical, and government research environments, with a focus on reproducibility and batch consistency critical for sensitive assays and diagnostic development. Award history is not available to infer specific agency relationships or project types, so no direct patterns of engagement with federal entities can be confirmed. However, given their NAICS classification and product focus, it is reasonable to infer potential alignment with research-focused agencies such as NIH, CDC, or DOD biomedical programs that require validated biological materials for infectious disease, immunology, or biosurveillance studies. The company’s primary industry focus is the biopharmaceutical manufacturing sector, specifically the production of research-grade biologicals used in preclinical and diagnostic workflows. Their market positioning is that of a specialized supplier serving the life sciences research ecosystem, with an emphasis on precision manufacturing rather than large-scale therapeutics production. NOVUS BIOLOGICALS, LLC is a small business structured as a 2K entity, headquartered in Englewood, Colorado. The company holds no federal certifications such as 8(a), HUBZone, or WOSB. Its geographic footprint is limited to its Colorado facility, and its government market positioning is that of a niche vendor supplying critical biological components to research and development programs requiring high-quality, traceable reagents.

Key Performance Metrics

Awards Count

98

All time

Active

0

Currently performing

Completed

98

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with NOVUS BIOLOGICALS, LLC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for NOVUS BIOLOGICALS, LLC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in NOVUS BIOLOGICALS, LLC's top NAICS codes and agencies

NAICS: 325413
New
DIBBS
CULTURE MEDIUM, THAYER-
Solicitation # SPE2DS-27-T-1066
Solicitation SPE2DS-27-T-1066 is a request for quotations issued by the DLA Troop Support Medical Supply Chain for the procurement of one package of Thayer-Martin Modified (MTM II) Agar culture medium, identified by NSN 6550-01-711-1542. This dark brown, ready-to-use plated medium is specifically designed for the isolation of pathogenic Neisseria from specimens containing mixed flora of bacteria and fungi. The product is delivered in packages of 100 plates and requires strict refrigeration storage between 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and must not be frozen. The contract mandates a non-extendable shelf life of three months, with a requirement that no more than 14 days elapse between the date of manufacture and the date of delivery to the government. Delivery is set for JBER, Alaska, with a required delivery date of October 27, 2026, under FOB Destination terms. Packaging must be commercial and sealed to prevent damage, with marking adhering to Medical Marking Standard No. 1 and shelf-life labels following MMS1C. Administrative requirements include electronic invoicing via the Wide Area WorkFlow system and compliance with various FAR and DFARS clauses, including the Buy American Act, Berry Amendment, and safeguarding of covered defense information. Evaluation will consider technical data for any alternate products offered and may include HUBZone price evaluation preferences. Inspection and acceptance will occur at the destination.
MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

about 8 hours ago

DEADLINE

in 6 days
View Details
NAICS: 541330
New
Federal
AIR FORCE CRYPTOLOGIC OFFICE COMMERCIAL SOLUTIONS OPENING
Solicitation # FA7037-21-S-C001
The Air Force Cryptologic Office Cyberspace Intelligence Surveillance and Reconnaissance and Multi-Domain Innovation Division is soliciting innovative commercial capabilities through Commercial Solutions Opening FA7037-21-S-C001. The agency is seeking mature technologies and services in Electromagnetic Warfare, Information Operations, and electromagnetic digital communications, with a specific goal of achieving a field demonstration within one year. This effort emphasizes the use of novel material approaches and innovative services, including a recent update to incorporate Super Intelligence. Awards may be issued as contracts or Other Transactions with periods of performance typically ranging from one to five years. The procurement follows a competitive two-phase submission process governed by 10 USC 3458 and DFARS 212.70. Phase I requires the submission of Quad Charts and White Papers, which are evaluated based on technical merit, importance to the AFCO mission, and fund availability. Offerors who are determined to be technically qualified may be invited to submit full Phase II proposals, including a detailed Statement of Work and a price proposal. All submissions are treated as commercial items, and offerors must possess the necessary personnel and facility security clearances to handle classified work in accordance with the National Industrial Security Program Operating Manual.
Department Of Defense

POSTED

about 13 hours ago

DEADLINE

in 11 months
View Details
NAICS: 325413
New
Federal
6550--Optilite analyzer reagents
Solicitation # 36C26227Q0052
The Department of Veterans Affairs, Southern Arizona Healthcare System, is soliciting a Firm-Fixed Price Blanket Purchase Agreement under solicitation 36C26227Q0052 for the procurement of FDA-approved reference testing reagents and consumables validated for use on the Optilite analyzer. The scope includes specific items such as Freelite Kappa, Freelite Lambda, and Ceruloplasmin reagents, as well as TENCELL cuvettes and sample cups. To ensure system performance and safety, all materials must be manufactured by Binding Site Laboratories, and substitutions are prohibited. The contract is issued as a full and open competition under NAICS code 325413, with a total estimated period of performance of sixty months, consisting of a base period from November 9, 2026, to November 8, 2027, followed by four one-year option periods. The award will be granted to the responsible offeror whose proposal is most advantageous to the government, based on a technical acceptability review of the Statement of Work and the lowest price. Deliveries are required to be made to various VA Medical Centers across Arizona, California, and New Mexico, with standard orders delivered within four working days of placement. All shipments must be destination-based, with the vendor assuming all shipping costs and adhering to strict packaging standards to prevent damage. Invoicing is handled electronically through the Department of Veterans Affairs Financial Services Center in accordance with the Prompt Payment Act. Quotes must be submitted via email to Contract Specialist Carlos Magana by November 4, 2026.
262-NETWORK Contract Office 22 (36C262)

POSTED

1 day ago

DEADLINE

in 7 days
View Details
NAICS: 325414
New
Federal
Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)
Solicitation # 12639527R0001
Solicitation 12639527R0001 is a request for proposal issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an unrestricted, IDIQ contract focused on Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC). The scope of work includes the purchase and storage of VAC, the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract features a ceiling price of 800 million dollars and a long-term performance horizon, consisting of five one-year ordering periods for VAC and direct purchases starting December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The contractor is required to produce VAC with a minimum capacity of 1.0 million doses and maintain storage on their premises under strict quality control and temperature monitoring standards. Due to the nature of the material, live FMDV is classified as a Tier 1 Select Agent, requiring specific authorization from the CDC/APHIS and adherence to rigorous shipping and security restrictions. Award will be based on the most advantageous offer, evaluating technical capability, past performance, and price, with technical and past performance factors weighted equally. Proposals must be submitted electronically in four separate volumes by November 10, 2026.
Mrpbs Minneapolis Mn

POSTED

1 day ago

DEADLINE

in 13 days
View Details